Children's Hospital Medical Center

Instituto Nacional De Ciencias Medicas Y Nutricion

The General Hospital Corporation

University of Massachusetts

Glycosyn LLC

Cincinnati Children's Hospital Medical Center

Ardythe L Morrow

David S Newburg

Guillermo M Ruiz-Palacios

John M McCoy

Michael A Helmrath

Lee A Denson

Lisa J Martin

Ethan Mezoff

John M Mccoy

A method of inhibiting inflammation with milk oligosaccharides or glycoconjugates containing the oligosaccharides.

Inhibiting inflammation with milk oligosaccharides

The invention provides compositions and methods for utilizing oligosaccharides, such as isolated human milk oligosaccharides, to attenuate a respiratory pathogen infection and/or to promote recovery from a respiratory pathogen infection in the respiratory system and/or the GI tract of a subject.

Fucosylated oligosaccharides for prevention of coronavirus infection

The invention provides compositions and methods for utilizing oligosaccharides, such as isolated human milk oligosaccharides, to attenuate a respiratory pathogen infection-induced host inflammation and/or to promote recovery from a respiratory pathogen infection-induced host inflammation in a subject.

2'-fucosyllactose for the prevention and treatment of coronavirus-induced inflammation

Provided herein are compositions and methods related to use of oligosaccharides, such as 2'-fucosyllactose, for increasing weight gain in a subject. In some aspects the compositions and methods are for use in infants, such as premature infants or infants having intestinal failure.

Use of oligosaccharide compositions to enhance weight gain

Diagnostic methods for assessing risk of or presence of inflammatory bowel disease in a patient based on glycosyltransferase or histo-blood group antigen signatures or a combination thereof. Also disclosed herein are prognostic methods for monitoring inflammatory bowel disease progression in a patient.

Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease

An individual at risk for necrotizing enterocolitis and related disorders can be identified by measuring the level of at least one secretor antigen in a biological sample from the individual and comparing the measured level of the at least one secretor antigen to a predetermined value or a predetermined range of values. Among the secretor antigens which can be measured are: the H-1, H-2, Lewisand Lewisantigens and derivatives thereof (e.g., a sialylated form of Lewis a, Lewis x, Lewis b, Lewis y; H-1, H-2, Lewis a, Lewis x, Lewis b or Lewis y).

Use of secretor, Lewis and sialyl antigen levels in clinical samples as predictors of risk for disease

Use of secretor, lewis and sialyl antigen levels in clinical samples as predictors of risk for disease

A method of inhibiting inflammation in a subject comprising the administration of milk oligosaccharides or glycoconjugates containing milk oligosaccharides is disclosed.

Methods for treating various disorders by orally administering adiponectin or a biologically active fragment thereof are described.

Adiponectin for treatment of various disorders

Oligosaccharides and oligosaccharides linked to backbones such as proteins, methods for making such oligosaccharides and methods for using them to treat and/or prevent various disorders are described.

Oligosaccharide compositions and use thereof in the treatment of infection

An individual at risk for necrotizing enterocolitis and related disorders can be identified by measuring the level of at least one secretor antigen in a biological sample from the individual and comparing the measured level of the at least one secretor antigen to a predetermined value or a predetermined range of values. Among the secretor antigens which can be measured are: the H-1 , H-2, Lewisand Lewisantigens and derivatives thereof (e.g., a sialylated form of Lewis a, Lewis x, Lewis b, Lewis y; H-1, H-2, Lewis a, Lewis x, Lewis b or Lewis y).

Growing community of inventors

Cincinnati, OH, United States of America

Ardythe L Morrow